not explain the trend. We can only speculate on factors such as subclinical infections, or length of daylight.
Summary
We report an analysis of 3,243 cases of squint examined at a health department clinic and an eye hospital. The estimated prevalence of squint at the age of 6 years is 4.3%, similar to estimates in other surveys in England. Incidence of onset is highest in the third year of life, and, if this distribution reflects the incidence in the community, it represents one characteristic pattern of distribution. Another pattern has been described in which the highest rate of onset is in the first year and diminishes rapidly thereafter. Non-central viewing occurs in 23% of the cases of squint in which this function could be assessed. Non-central viewing is much more frequent in boys, in children in whom the onset is early, in those who have had the squint for a longer period, and in those with high degrees of anisometropia. There is evidence that squints begin more often in winter, with a peak incidence in January.
We are indebted to Mrs. Anne Fish for her painstaking and careful handling of the data, 'and to Professor C. I. Phillips for his advice. We wish to thank the surgeons at the Manchester Royal Eye Hospital for making available for examination cases under their care.
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Progestin Therapy of Breast Cancer: Comparison of Agents BASIL A. STOLL,* M.R.C.S., F.F.R. Brit. med. J., 1967, 3, 338 -341 Over recent years many synthetic orally active progestational agents have been introduced to clinical practice. The multiplicity of such agents presents a problem of choice to the clinician considering progestin therapy in breast cancer. A similar problem applies also to uterine cancer. Various authors, each using a different progestin, have reported their results in small series of breast cancer cases (Jonsson et al., 1959 ; Lewin et al., 1959; Douglas et al., 1960; Baker and Kelley, 1960; Jolles, 1962; Bucalossi et al., 1963 ; Stoll, 1965) . The trials are summarized in Table I , and from the results it is obvious that there is a place for progestin therapy in breast cancer. To our knowledge no basis has yet been shown for statements that the presence of breast cancer contraindicates the use of progestins because they may possibly stimulate the tumour (Klawans, 1965) . Jonsson et al. (1959) .. Bromoketoprogesterone 7 of 34 Lewin et al. (1959) . eight months when the drug was continued. Details of response for each patient are shown in Table II , and for each group in Table III . 
Results
Objective response as defined above was noted in 12 of the 65 patients. It was seen in 3 out of 19 cases on the 19-nortestosterone derivatives, in 5 out of 28 on the 17a-hydroxyprogesterone derivatives, and in 4 out of 18 on the testosterone derivative. In the last group there were 8 additional cases where the observed lesions showed regression but less than 50% reduction in size. There is no statistically significant difference in tumour response rate between the groups (Table III) . However, the selected example of the testosterone derivatives (dimethisterone) differs in one respect from the other groups in that it yields a high proportion of patients with partial response, similar to that seen from corticosteroid administration (Stoll, 1963) . The dose level selected for dimethisterone appears to be near its minimum effective level, as shown in four of these patients where the dosage was halved when the disease appeared to be partially under control. In two of these patients with nodular infiltration of the chest wall the symptoms of itching and tightness, which had eased at full dosage, reappeared at half dosage, but eased again when full dosage was reinstituted.
Of the 65 patients assessed for tumour response on progestins, 40 had undergone a previous trial of oestrogen or androgen therapy (Table IV) . When comparing patients previously responding with those not responding to oestrogen or androgen therapy there is no statistical difference in the proportion of progestin responders (Table IV) . Of eight progestin responders who had received a previous trial of oestrogens or androgens, only two had responded to these agents. It has also been reported (Stoll, 1966) (Stoll et al., 1966) . In the present series there were no cases with clinical signs of jaundice or a raised bilirubin level.
Glucose-tolerance tests were carried out in eight cases after at least four weeks' drug administration. Abnormally high blood glucose levels after one hour were noted in one of the eight cases (compared with three of four cases in a similar therapeutic trial of Lyndiol (Stoll 1967a) ). The liver-function tests showed no gross abnormality in the patients with abnormal blood glucose levels.
Pretreatment Vaginal Smear
The adrenal cortex secretes androgens throughout life in the female. In addition, the secretion of oestrogens and progesterone does not cease with atrophy of the ovary at the menopause, as breakdown products of both these corticosteroids have been shown in the urine in postmenopausal women (Klopper et al., 1955 ; Nissen-Meyer and Sanner, 1963 (Struthers, 1956 ; Finkbeiner, 1960 (Atkins, 1966) . It is interesting that in (Stoll, 1967b) . (Stoll, 1967a) The 19-nortestosterone derivatives used in this trial are norethisterone acetate (17a-ethynyl derivative) and lynoestrenol (17a-ethynyl-3-deoxy derivative). Some members of this group show oestrogenic properties and, in addition, the group tends to be androgenic in experimental animals.
The 17a-hydroxyprogesterone derivatives used in this trial are medroxyprogesterone (6-methyl derivative), megestrol (6-dehydro-6-methyl derivative), and melengestrol (16-methylene derivative of megestrol). The testosterone derivative used was dimethisterone (6a,21-dimethylethisterone). These latter two groups of compounds are said to possess no inherent oestrogenicity and no significant androgenic activity in the experimental animal (Goldzieher, 1964 (Table II) .
Discussion
By definition, a progestational agent is one which causes a secretory response in the uterine lining after oestrogen priming. The many synthetic orally active progestational agents available have marked qualitative differences in their oestrogenicity, androgenicity, and metabolic activity. We prefer to use the term "progestins " rather than " progestogens " or " progestational agents," because their major clinical use in recent years has not been for assistance in the initiation of pregnancy. The mode of action of progestins in breast cancer may be by:
1. Effect on Anterior Pituitary Secretion.-There is conflicting evidence concerning the effect of progestins on total gonadotrophin excretion (Brown et al., 1964) . Nevertheless, it is possible that a decrease in the luteotrophin secretion alone may be the effect common to these agents (Diczfalusy, 1965) . They are also said to stimulate release of mammotropin from the pituitary (Kim, 1965 Kim's (1965) observation that in the hypophysectomized animal there is a growthpromoting effect on hormone-sensitive mammary cancer by the combined administration of oestradiol and progesterone, but not from oestrogens alone. growth, but its combination with 4 mg. of progesterone daily will actually extinguish tumour growth in the majority. Young et at. (1963) noted that the administration of oestradiol after oophorectomy causes tumour reactivation in less than 50% of such rats, but the addition of progesterone causes reactivation in 95% of cases. Similarly, though Sterental et al. (1963) showed no reactivation of the experimental cancer by oestrogen administration after hypophysectomy, Kim (1965) noted that the combination of oestradiol and progesterone has a very potent growth-promoting effect in the hypophysectomized animal. All these observations can be interpreted as suggesting a fourth possible mode of action of progestins in breast cancer. It is possible that progesterone acts by sensitizing experimental mammary cancer in rats to the action of oestrogens, whether in the form of stimulation or of depression of tumour growth. If this applies to man one would not expect to obtain significant response of breast cancer to progestin therapy in the absence of oestrogens. This may account for the very poor response rate seen in patients with an atrophic vaginal smear, as such a smear indicates a complete absence of oestrogen stimulation in the postmenopausal woman.
A previous paper (Stoll, 1967a) reported the effect on advanced breast cancer of Lyndiol, a commercially available oral contraceptive containing lynoestrenol, a progestin of the 19-norsteroid group, combined with the oestrogen mestranol. The proportion of responders was similar to that noted in this paper for progestin-treated cases (Table V) . The addition of oestrogen (in the form and dose found in Lyndiol) does not seem to increase the response rate in the patient with an atrophic vaoinal smear.
There may be some selectivity of action by particular progestins. There were five patients to whom dimethisterone was given after failure of previous progestins, and in two of them tumour response (by full criteria) was noted. However, dimethisterone given to five patients after failure of Lyndiol gave no response. It is suggested that the metabolism of different progestins might be investigated in breast cancer patients by the administration of radioactively tagged progestins. This would establish whether there is indeed a direct effect on the target organ cells. In addition, the distribution of the radioactive hormone in the tumour could be estimated by autoradiography, since localization is probably not uniform and depends on vascularity, patchy necrotic changes, or other factors.
Summary
The effect of representatives of the three major groups of progestins is compared on metastatic soft-tissue growth of breast cancer in postmenopausal women.
Objective regression of soft-tissue tumour was noted in 12 out of 65 patients treated for two months or longer. Differences in side-effects and liver toxicity between the groups are noted. In addition, a corticosteroid-like effect of one agent on breast cancer is noted.
It is possible to differentiate patients with a 29% likelihood of response from those with only a 5 % likelihood of response by cytohormonal examination of the postmenopausal vaginal smear before therapy.
The possible mode of action of progestins in breast cancer is discussed.
My thanks are due to Dr. W. J. Moon for many stimulating discussions in the course of this project.
